$1.64
0.074.46%
At Close: -
$1.67
0.031.83%
After Hours: Jul 19, 6:20 PM EDT
15 minutes delayed
Comments
Loading...
Coherus BioSciences
CHRSNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Coherus BioSciences (NASDAQ:CHRS) Stock, Analyst Ratings, Price Targets, Forecasts
Coherus BioSciences Inc has a consensus price target of $11.13 based on the ratings of 9 analysts. The high is $21 issued by Mizuho on November 16, 2022. The low is $7 issued by Truist Securities on May 13, 2024. The 3 most-recent analyst ratings were released by Baird, HC Wainwright & Co., and Truist Securities on July 1, 2024, May 24, 2024, and May 13, 2024, respectively. With an average price target of $9 between Baird, HC Wainwright & Co., and Truist Securities, there's an implied 438.92% upside for Coherus BioSciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Baird
HC Wainwright & Co.
Truist Securities
Barclays
Citigroup
1calculated from analyst ratings
Analyst Ratings for Coherus BioSciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/01/2024 | Buy Now | 379.04% | Baird | Colleen Kusy | $9 → $8 | Maintains | Outperform | Get Alert |
| 05/24/2024 | Buy Now | 618.56% | HC Wainwright & Co. | Douglas Tsao | → $12 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | 319.16% | Truist Securities | Robyn Karnauskas | $8 → $7 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 618.56% | HC Wainwright & Co. | Douglas Tsao | $11 → $12 | Maintains | Buy | Get Alert |
| 03/20/2024 | Buy Now | 558.68% | HC Wainwright & Co. | Douglas Tsao | $13 → $11 | Maintains | Buy | Get Alert |
| 03/14/2024 | Buy Now | 678.44% | HC Wainwright & Co. | Douglas Tsao | → $13 | Reiterates | Buy → Buy | Get Alert |
| 01/23/2024 | Buy Now | 438.92% | Baird | Colleen Kusy | $11 → $9 | Maintains | Outperform | Get Alert |
| 01/23/2024 | Buy Now | 379.04% | Truist Securities | Robyn Karnauskas | $12 → $8 | Maintains | Buy | Get Alert |
| 12/27/2023 | Buy Now | 678.44% | HC Wainwright & Co. | Douglas Tsao | → $13 | Reiterates | Buy → Buy | Get Alert |
| 12/07/2023 | Buy Now | 678.44% | HC Wainwright & Co. | Douglas Tsao | → $13 | Reiterates | Buy → Buy | Get Alert |
| 11/28/2023 | Buy Now | 618.56% | Truist Securities | Robyn Karnauskas | → $12 | Reiterates | Buy → Buy | Get Alert |
| 11/17/2023 | Buy Now | 558.68% | Baird | Colleen Kusy | → $11 | Initiates | → Outperform | Get Alert |
| 11/08/2023 | Buy Now | — | Maxim Group | Jason McCarthy | — | Downgrade | Buy → Hold | Get Alert |
| 11/07/2023 | Buy Now | 678.44% | HC Wainwright & Co. | Douglas Tsao | $20 → $13 | Maintains | Buy | Get Alert |
| 10/23/2023 | Buy Now | 319.16% | Barclays | Balaji Prasad | $8 → $7 | Maintains | Overweight | Get Alert |
| 09/26/2023 | Buy Now | 1097.6% | Truist Securities | Robyn Karnauskas | → $20 | Reiterates | Buy → Buy | Get Alert |
| 09/26/2023 | Buy Now | 1097.6% | HC Wainwright & Co. | Douglas Tsao | → $20 | Reiterates | Buy → Buy | Get Alert |
| 08/03/2023 | Buy Now | 1097.6% | HC Wainwright & Co. | Douglas Tsao | $24 → $20 | Maintains | Buy | Get Alert |
| 07/24/2023 | Buy Now | 618.56% | Citigroup | Robyn Karnauskas | → $12 | Initiates | → Buy | Get Alert |
| 07/14/2023 | Buy Now | 1097.6% | Truist Securities | Robyn Karnauskas | $22 → $20 | Maintains | Buy | Get Alert |
| 06/28/2023 | Buy Now | 1217.37% | Truist Securities | Robyn Karnauskas | → $22 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2023 | Buy Now | 1217.37% | Truist Securities | Robyn Karnauskas | $24 → $22 | Maintains | Buy | Get Alert |
| 06/20/2023 | Buy Now | 1337.13% | HC Wainwright & Co. | Douglas Tsao | → $24 | Reiterates | Buy → Buy | Get Alert |
| 06/15/2023 | Buy Now | 1337.13% | Truist Securities | Robyn Karnauskas | → $24 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2023 | Buy Now | 1337.13% | HC Wainwright & Co. | Douglas Tsao | → $24 | Reiterates | → Buy | Get Alert |
| 06/01/2023 | Buy Now | 1337.13% | HC Wainwright & Co. | Douglas Tsao | → $24 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2023 | Buy Now | 379.04% | Barclays | Balaji Prasad | $13 → $8 | Maintains | Overweight | Get Alert |
| 05/09/2023 | Buy Now | 1337.13% | HC Wainwright & Co. | Douglas Tsao | $26 → $24 | Maintains | Buy | Get Alert |
| 05/01/2023 | Buy Now | 1337.13% | Truist Securities | Robyn Karnauskas | → $24 | Initiates | → Buy | Get Alert |
| 03/28/2023 | Buy Now | 558.68% | UBS | Ashwani Verma | → $11 | Upgrade | Neutral → Buy | Get Alert |
| 03/08/2023 | Buy Now | 678.44% | Barclays | Balaji Prasad | $15 → $13 | Maintains | Overweight | Get Alert |
| 03/07/2023 | Buy Now | 1456.89% | HC Wainwright & Co. | Douglas Tsao | $30 → $26 | Maintains | Buy | Get Alert |
| 11/16/2022 | Buy Now | 1157.49% | Mizuho | Salim Syed | $28 → $21 | Maintains | Buy | Get Alert |
| 11/14/2022 | Buy Now | 558.68% | JP Morgan | Chris Schott | $13 → $11 | Maintains | Neutral | Get Alert |
| 08/16/2022 | Buy Now | 1576.65% | Mizuho | Salim Syed | $25 → $28 | Maintains | Buy | Get Alert |
| 06/14/2022 | Buy Now | 319.16% | UBS | Ashwani Verma | → $7 | Initiates | → Neutral | Get Alert |
| 05/20/2022 | Buy Now | 1397.01% | Mizuho | Salim Syed | $30 → $25 | Maintains | Buy | Get Alert |
| 05/09/2022 | Buy Now | 798.2% | Barclays | Balaji Prasad | $20 → $15 | Maintains | Overweight | Get Alert |
| 03/07/2022 | Buy Now | 798.2% | JP Morgan | Chris Schott | → $15 | Downgrade | Overweight → Neutral | Get Alert |
| 11/09/2021 | Buy Now | 1696.41% | HC Wainwright & Co. | Douglas Tsao | — | Maintains | Buy | Get Alert |
| 07/23/2021 | Buy Now | 2055.69% | HC Wainwright & Co. | Douglas Tsao | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Coherus BioSciences (CHRS) stock?
The latest price target for Coherus BioSciences (NASDAQ:CHRS) was reported by Baird on July 1, 2024. The analyst firm set a price target for $8.00 expecting CHRS to rise to within 12 months (a possible 379.04% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Coherus BioSciences (CHRS)?
The latest analyst rating for Coherus BioSciences (NASDAQ:CHRS) was provided by Baird, and Coherus BioSciences maintained their outperform rating.
When was the last upgrade for Coherus BioSciences (CHRS)?
The last upgrade for Coherus BioSciences Inc happened on March 28, 2023 when UBS raised their price target to $11. UBS previously had a neutral for Coherus BioSciences Inc.
When was the last downgrade for Coherus BioSciences (CHRS)?
The last downgrade for Coherus BioSciences Inc happened on November 8, 2023 when Maxim Group changed their price target from N/A to N/A for Coherus BioSciences Inc.
When is the next analyst rating going to be posted or updated for Coherus BioSciences (CHRS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Coherus BioSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Coherus BioSciences was filed on July 1, 2024 so you should expect the next rating to be made available sometime around July 1, 2025.
Is the Analyst Rating Coherus BioSciences (CHRS) correct?
While ratings are subjective and will change, the latest Coherus BioSciences (CHRS) rating was a maintained with a price target of $9.00 to $8.00. The current price Coherus BioSciences (CHRS) is trading at is $1.67, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.